Us Dermatology Partners -Dr Bryan Townsend

CLIA Laboratory Citation Details

3
Total Citations
14
Total Deficiencyies
6
Unique D-Tags
CMS Certification Number 45D0947411
Address 8044 Shoal Creek Boulevard, Austin, TX, 78757
City Austin
State TX
Zip Code78757
Phone(512) 459-1269

Citation History (3 surveys)

Survey - November 7, 2024

Survey Type: Standard

Survey Event ID: HUQ911

Deficiency Tags: D0000 D3031 D3041 D5463 D0000 D3031 D3041 D5463

Summary:

Summary Statement of Deficiencies D0000 The laboratory was surveyed and found to be in compliance with the Conditions of the CLIA regulations found at 42 CFR 493.1 through 493.1780, and recertification is recommended. Standard level deficiencies were cited. D3031 RETENTION REQUIREMENTS CFR(s): 493.1105(a)(3) Analytic systems records. Retain quality control and patient test records (including instrument printouts, if applicable) and records documenting all analytic systems activities specified in 493.1252 through 493.1289 for at least 2 years. This STANDARD is not met as evidenced by: Based on review of the reagent log, interview, and presurvey paperwork, the laboratory failed to retain the chemical name and concentration (if applicable), manufacturer, lot number, expiration date, received date, and open date of the chemicals and stains used in the laboratory for Mohs testing for two of two years reviewed. Findings follow. A. Review of the reagent log from 12/2022 - 11/07/2024 was missing the documentation of the chemicals and stains (Bluing, 100% Reagent Alcohol, Acid Rinse, UltraClear, Neg-50, etc.) other than for Hematoxylin and Eosin. B. Interview with the Office Manager/ Mohs tech on November 7, 2024 at 1415 hours in the breakroom confirmed the findings C. Review of the CMS Form 116 showed an estimated annual volume of 3000 blocks. D3041 RETENTION REQUIREMENTS CFR(s): 493.1105(a)(6) Test reports. Retain or be able to retrieve a copy of the original report (including final, preliminary, and corrected reports) at least 2 years after the date of reporting. (i) In addition, retain immunohematology reports as specified in 21 CFR 606.160(d) (ii) and pathology test reports for at least 10 years after the date of reporting. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- This STANDARD is not met as evidenced by: Based on review of patient test reports, slides, interview, and pre-survey paperwork, the laboratory failed to ensure Mohs test reports were available for at least 10 years from the report date for three out of 10 cases from 11/07/2014 to 12/31/2017. Findings follow. A. Random review of 10 Mohs cases from 11/07/2014 to 12/31/2017 showed the test reports and maps were unavailable for review for three cases as listed by date and case number: Date Case # 1. 12/03/2014: 700 2. 01/21/2015: 20 3. 07/21 /2015: 479 B. Interview with the Office Manager/Mohs tech on November 7, 2024 at 1520 hours in the breakroom stated the EMR was replaced and they took away access to the old system (EMD) and they no longer had access to old reports and maps of patients that have not been seen at the clinic since they switched to EMA in May 2017. There was no way of knowing which reports were available without pulling each individual chart. C. Review of the CMS Form 116 showed an estimated annual test volume of 3000 blocks. KEY: EMA = Electronic Medical Access D5463 CONTROL PROCEDURES CFR(s): 493.1256(d)(7)(g) Unless CMS Approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub. 7), that provides equivalent quality testing, the laboratory must-- Over time, rotate control material testing among all operators who perform the test. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on a review of quality control (QC) records and interview, the laboratory failed to ensure quality control for the Hematoxylin and Eosin stain was performed among testing personnel providing a diagnostic interpretation in Mohs testing for 19 out of 24 months from November 2023 - October 2024. Findings follow. A. Review of the laboratory's policy and procedure titled Histopathology Mohs Surgery, revised 01/10 /2024, at 7.4 Staining Procedure in Mohs Lab stated, "For quality assurance purposes, the technician will examine the first slide, control slide, run through the staining process. The technician will mark the control slide with the date of testing. The results will be recorded each day in the quality control log." While it is good laboratory practice for the histotech (or Mohs tech) to review the control slide, it is the responsibility of the testing personnel (Mohs surgeon) to perform the QC and document. B. Review of the Daily Quality Control Log: H&E Stain from 11/01/2022 - 10/31/2024 showed the Mohs tech performed and documented QC from April 2023 - October 2024. C. Interview with the Office Manager/ Mohs tech on November 7, 2024 at 1350 hours in the breakroom stated she would look at the slide and document and give the slides to the Mohs surgeon and was following the procedure. D. Review of the CMS Form 116 showed an estimated annual volume of 3000 blocks. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - November 17, 2022

Survey Type: Standard

Survey Event ID: N7MW11

Deficiency Tags: D0000 D5473 D0000 D5473

Summary:

Summary Statement of Deficiencies D0000 Noted deficiencies and plans of correction were discussed with the laboratory representative at the exit conference. The facility was found to be in compliance with applicable Conditions of Participation in the CLIA program, and recertification is recommended. D5473 CONTROL PROCEDURES CFR(s): 493.1256(e)(2)(g) (e) For reagent, media, and supply checks, the laboratory must do the following: (e) (2) Each day of use (unless otherwise specified in this subpart), test staining materials for intended reactivity to ensure predictable staining characteristics. Control materials for both positive and negative reactivity must be included, as appropriate. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on internet search, review of quality control (QC) records, and interview, the laboratory failed to include the intended reactivity of the Hematoxylin and Eosin stain to ensure predictable staining characteristics on their quality control log used to document stain quality for Mohs testing for 5 out of 5 months reviewed. Findings follow. A. Internet search of the stains used in the laboratory during the survey showed no definitions of staining characteristics of the stain. The laboratory presented the surveyor with the ASMH Frozen Section Manual Chapter 10 titled Staining which stated, "Gill 3 hematoxylin stains nuclei blue-black" whereas Eosin Y stains the "cytoplasmic and extracellular proteins" [pink] and "helps to ensure crisp staining". B. Review of the Daily Quality Control Log: H&E Stain showed from 06/01/2022 - 10/31 /2022 the QC was deemed to be either acceptable or unacceptable with no definition of what "acceptable" was. C. Interview with the histotech on November 17, 2022, at 0945 hours in the laboratory confirmed the staining characteristics were not included on the quality control log. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - November 1, 2018

Survey Type: Standard

Survey Event ID: V4G611

Deficiency Tags: D5413 D5413

Summary:

Summary Statement of Deficiencies D5413 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(b) The laboratory must define criteria for those conditions that are essential for proper storage of reagents and specimens, accurate and reliable test system operation, and test result reporting. The criteria must be consistent with the manufacturer's instructions, if provided. These conditions must be monitored and documented and, if applicable, include the following: (1) Water quality. (2) Temperature. (3) Humidity. (4) Protection of equipment and instruments from fluctuations and interruptions in electrical current that adversely affect patient test results and test reports. This STANDARD is not met as evidenced by: Based on review of the cryostat operator's manual, laboratory environmental records, and interview with facility personnel, the laboratory failed to monitor the humidity of the operating environment for 10 of 10 months between January 1, 2018 and October 31, 218. The findings included: 1. Based on review of the Thermo Scientific Cryostat Microm HM 525 Technical Data, on page 12 of the operator's manual, the document states the following: "Operating Requirements: 5 degrees Celsius up to 35 degrees Celsius (at a max relative humidity of 60 percent)." 2. Based on a review of environmental laboratory records from 2018, the laboratory had recorded laboratory temperatures but failed to records laboratory humidity levels for 10 of 10 months between January 2018 and October 2018. The laboratory performs testing three days per week. 3. In an interview with the Laboratory Manager at 10:53 hours on 11/01 /2018, the Laboratory Manager stated the laboratory had the necessary equipment needed to monitor humidity levels but had not kept the documentation of humidity levels previously. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access